Compare ConocoPhillips (COP) vs 10X Genomics Inc (TXG) Price & Performance

ConocoPhillips (COP) trades at $134.52, up 3.6% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global. Valuation metrics appear reasonable with P/E at 17.75 and EV/EBITDA at 6.36, while profitability remains solid with 14.65% net income margin and 14.14% ROE.

Outlook remains positive with consensus price target of $154.75 representing 15% upside potential. Key risks include oil price volatility and geopolitical exposure in international operations. The company's strong cash flow generation and strategic LNG expansion provide growth catalysts, though investors should monitor execution on asset sales and energy market dynamics.

TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.

The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.